Stocks in play: Oncolytics Biotech Inc
Announced it has entered into a preliminary collaboration with the Global Coalition for Adaptive Research. The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma as part of GCAR's anticipated master protocol for metastatic pancreatic cancer. Activities are currently underway to finalize the seamless Phase 2/3 master protocol design that will evaluate multiple investigational therapies for the treatment of pancreatic cancer. An intent of the study is to produce registration-enabling data. Oncolytics Biotech Inc shares T.ONC are trading up $0.02 at $1.62.
Read:
Lithium's Future Looks Bright: Demand Expected to Surge by 1,500% by 2050 According to IEA Data
Biotech Innovations Drive Hope in Global Fight Against Pancreatic Cancer
Data Center Infrastructure Management Market on Track for Rapid Growth
Tech Firms Innovate Amidst AI Boom, Eyeing $266 Billion Generative Market